

2018/12/21

The 4th NCGM International Infectious Diseases Forum

# MERS outbreak and its response in Japan

National Center for Global health and Medicine

Disease Control and Prevention Center

Satoshi Kutsuna, M.D., PhD.



# NCGM

Disease Control and Prevention Center

# about DCC

- Clinical Infectious Diseases (about 15 beds, and ID consultation)
- Travel Clinic
- Emerging Infectious Diseases
- Infection Prevention and Control
- AMR Clinical Reference Center
- Antimicrobial Stewardship

# staff for EID patients

- 16 ID doctors(belong to DCC)
- about 20 nurses(usually belong to each inpatients ward)
- Intensivists will attend the care for EID, if necessary
- Other medical specialists will give advises for each specialty
- Laboratory technician, clinical engineer, and radiation technologist





本館用  
PPE 3  
M...

足袋

清潔

清潔

清潔

清潔


清潔

清潔

清潔










# 4 suspected EVD cases in NCGM

Cases	date	countries	ebola PCR	duration of isolation	final diagnosis
40s M	2014/10/27	unknown	-ve	3 days	unknown
60s M	2014/11/7	Liberia	-ve	2 days	Streptococcal pharyngitis
30s M	2014/12/29	Sierra Leone	-ve	2 days	sinusitis
70s F	2015/1/18	Sierra Leone	-ve	3 days	influenza A



# FilmArray® multiplex PCR system

- Simple: 2 minutes of hands-on time
- Easy: No precise measuring or pipetting required
- Fast: Turnaround time of about an hour





Laboratory in ID unit.

- CBC and chems
- Rapid Test  
(Malaria, Dengue, etc..)
- PCR(EVD)

# 4 suspected MERS cases in NCGM


Cases	date	countries	MERS PCR	duration of isolation	final diagnosis
20s F	2015/6/16	Korea	-ve	2 days	Bronchitis
10s F	2016/1/3	UAE	-ve	2 days	Influenza B
40s M	2015/1/6	Dobai	-ve	2 days	Streptococcus pyogenes pneumonia
70s F	2015/1/18	Qatar	-ve	2 days	influenza A

# LAMP method for MERS-CoV detection

- Loop-mediated Isothermal Amplification is a simple, rapid, specific and cost-effective nucleic acid amplification method solely developed by Eiken Chemical Co., Ltd.
- It takes only 30 minutes to detect pathogens including MERS-CoV.
- We have multiplex LAMP method system in our laboratory in ID unit.



# Chip Layout



3cm

Chip Layout is designed by Dr. Kageyama, National Institute of Infectious Diseases, Japan and EIKEN Chemical Co., Ltd.



Stand-by **STOP**

150P 150R Unit-3 Unit-4


Comment Sample name: 20160101  
 Chip ID: H-0154  
 Chip type: No.6

Information Tray state: CLOSE Heater temp.(Upper): 0.0 °C Mass time: 30 min  
 Chip state: NONE (Lower): 0.0 °C Remain time:

Well Information

1 <input checked="" type="checkbox"/> MFRG	None	2 <input checked="" type="checkbox"/> MFRG	1.7	None	3 <input checked="" type="checkbox"/>	None	4 <input checked="" type="checkbox"/>	None	5 <input checked="" type="checkbox"/>	None	
6 <input checked="" type="checkbox"/> FLUA	-	None	7 <input checked="" type="checkbox"/> FLUB	+	9.58	8 <input checked="" type="checkbox"/> H1pdm	-	None	9 <input checked="" type="checkbox"/> H3	-	None
11 <input checked="" type="checkbox"/> FLUA	-	None	12 <input checked="" type="checkbox"/> FLUB	+	9.1	13 <input checked="" type="checkbox"/> H1pdm	-	None	14 <input checked="" type="checkbox"/> H3	-	None
16 <input checked="" type="checkbox"/> FLUA	-	None	17 <input checked="" type="checkbox"/> FLUB	+	9.45	18 <input checked="" type="checkbox"/> H1pdm	-	None	19 <input checked="" type="checkbox"/> H3	-	None
21 <input checked="" type="checkbox"/> FLUA	None	22 <input checked="" type="checkbox"/> FLUB	1	U.S'	23 <input checked="" type="checkbox"/> H1pdm	None	24 <input checked="" type="checkbox"/> H3	None	25 <input checked="" type="checkbox"/> H7N9	None	

Real-time graph Measurement data





1502

1508

Unit-3

Unit-4

**Comment** Sample name : 20160104  
 Chip ID : 11-0154  
 Chip type : No.6


**Information** Tray state : CLO  
 Chip state : NOM

**Well information**

1	<input checked="" type="checkbox"/>	<span style="color:red">■</span> MERS	-	None	2	<input checked="" type="checkbox"/>	<span style="color:red">■</span> MERS	+/-	None	3	<input checked="" type="checkbox"/>	<span style="color:red">■</span>	-	None	4	<input checked="" type="checkbox"/>	<span style="color:red">■</span>	-	None
6	<input checked="" type="checkbox"/>	<span style="color:blue">■</span> FLUA	-	None	7	<input checked="" type="checkbox"/>	<span style="color:gray">■</span> FLUB	+	9.58	8	<input checked="" type="checkbox"/>	<span style="color:orange">■</span> H1pdm	-	None	9	<input checked="" type="checkbox"/>	<span style="color:yellow">■</span> H3	-	None
11	<input checked="" type="checkbox"/>	<span style="color:blue">■</span> FLUA	-	None	12	<input checked="" type="checkbox"/>	<span style="color:gray">■</span> FLUB	+	9.11	13	<input checked="" type="checkbox"/>	<span style="color:orange">■</span> H1pdm	-	None	14	<input checked="" type="checkbox"/>	<span style="color:yellow">■</span> H3	-	None
16	<input checked="" type="checkbox"/>	<span style="color:blue">■</span> FLUA	-	None	17	<input checked="" type="checkbox"/>	<span style="color:gray">■</span> FLUB	+	9.45	18	<input checked="" type="checkbox"/>	<span style="color:orange">■</span> H1pdm	-	None	19	<input checked="" type="checkbox"/>	<span style="color:yellow">■</span> H3	-	None
21	<input checked="" type="checkbox"/>	<span style="color:blue">■</span> FLUA	-	None	22	<input checked="" type="checkbox"/>	<span style="color:gray">■</span> FLUB	+	8.91	23	<input checked="" type="checkbox"/>	<span style="color:orange">■</span> H1pdm	-	None	24	<input checked="" type="checkbox"/>	<span style="color:yellow">■</span> H3	-	None

Real-time graph

Measurement data



# Medical system for MERS in Japan

# Classification of Infectious Disease Law in Japan

Type 1  
(7)

Viral Hemorrhagic Fever  
EVD  
Lassa Fever  
CCHF  
Marburg disease  
South American  
Hemorrhagic Fevers  
  
Plague  
Smallpox

Type 2  
(7)

Tuberculosis  
**MERS**  
SARS  
Avian flu  
(H5N1/H7N9)  
Polio  
Diphtheria

Type 3  
(5)

Cholera  
Typhoid fever  
Paratyphoid fever  
Dysentery  
EHEC infection

Type 4  
(44)

Dengue  
Zika  
Chikungunya  
Yellow Fever  
Hepatitis A  
Legionellosis  
SFTS  
Rabies  
etc...

# Classification of Medical Center in Infectious Disease Law in Japan

New Infectious Diseases	Type I Infectious Diseases	Type II Infectious Diseases	Others
-------------------------	----------------------------	-----------------------------	--------

4 Medical institutions designated for **specific** infectious diseases

54 Medical institutions designated for **type I** infectious diseases

347 Medical institutions designated for **type II** infectious diseases

not designated

# Medical institutions designated for specific infectious diseases


4 Hospitals located near international airports

Rinku Medical Center  
(Kansai Airport: KIX)


Narita Red Cross Hospital  
(Narita Airport: NRT)

NCGM  
(Haneda Airport: HND)

Tokoname City Hospital  
(Centrair Airport: NGO)




# Medical institutions designated for **type I** infectious diseases



54 Hospitals located  
almost every prefectures

see patients of Ebola, MERS etc.

# Medical institutions designated for **type II** infectious diseases



347 Hospitals located  
every secondary medical care area

see patients of MERS, Avian flu etc.

# The Number of hospitals which see patients of MERS in Japan

$$\begin{array}{ccccccc} 4 & + & 54 & + & 347 & = & 405 \\ \text{specific} & & \text{type I} & & \text{type II} & & \end{array}$$

**405 Hospitals are designated for MERS  
,not only diagnosis, but also treatment.**

**But...is it possible?**

# Why MERS is type 1 infectious diseases in law?

	Ebola	MERS	Avian flu H7N9
Fatality Rate	39.5% (west Africa)	34.9%	38.9% (China)
Number of reproductions	1.5-2.5 (west Africa)	8.0977 (Korea)	0.07 (China)
Transmission	body fluid	droplets (aerosol)	droplets (aerosol)
Classification of Infectious Disease Law	1	2	2

PLoS Curr. 2014 Sep 2;6. pii: ecurrents.outbreaks.  
 Biomed Eng Online. 2017 Jun 13;16(1):79.  
 BMJ. 2015 Nov 19;351:h5765.

平成 29 年 12 月 15 日

**In Medical institutions designated for type I infectious diseases (44 HPs)**

**Fear of accepting patients due to insufficient system(23%; 11/44)**

**There is no full-time infectious disease specialist(50%; 22/44)**

**Not assume the number of medical staff required per infectious disease patient or the organizational planning of medical team(23%; 11/44)**

	specific type I	type II
Infection Control Nurses	93%	83.3%
Infectious Diseases Doctors	65.1%	16%
Intensivists	59.0%	25.0%
Pediatrics Intensivists	26.3%	7.2%

Ishikane, Morioka, Kutsuna, Ohmagari. In press

	specific type I	type II
Number of doctors who attend care for EID patients	1-15 (median: 3)	0-6 (median: 1.5)
Hospitals which have 7 or more doctors for EID patients	10.3%	0%
Number of nurses who attend care for EID patients	0-65 (median: 15)	0-30名 (median: 3)
Number of clinical laboratory technician for EID patients	0-9 (median: 2)	0-3 (median: 1)
Number of Radiologist for EID patients	0-6 (中央値: 1)	0-3 (median: 0)

# Preparing U.S. Hospitals for Ebola



U.S. Department of Health and Human Services  
Centers for Disease Control and Prevention

**CDC** has developed a strategy to help healthcare facilities and state health officials prepare for patients with possible or confirmed Ebola. This strategy identifies which hospitals will provide different levels of care for patients being assessed and treated for Ebola.



## Frontline Healthcare Facility



Quickly identifies and isolates patients with possible Ebola



Notifies facility infection control and state and local public health officials



Has enough Ebola personal protective equipment (PPE) for at least 12–24 hours of care

Prepares for patient transfer, if needed



## Ebola Assessment Hospital



Safely receives and isolates a patient with possible Ebola



Provides immediate laboratory evaluation and coordinates Ebola testing



Cares for a patient for up to 96 hours (including evaluation and management of alternative diagnoses) until Ebola diagnosis is confirmed or ruled out



Has enough Ebola PPE for up to 96 hours of care

Transfers a patient with confirmed Ebola to an Ebola treatment center in consultation with public health officials



## Ebola Treatment Center



Safely receives and isolates a patient with confirmed Ebola



Cares for patients with Ebola for duration of illness



Has enough Ebola PPE for at least 7 days of care (will restock as needed)



Has sustainable staffing plan to manage several weeks of care



CDC experts are ready to deploy to provide assistance as needed

### All of the hospitals will be prepared to do the following:

Ensure staff are appropriately trained and have documented competency in safe PPE practices



Have systems in place to safely manage waste disposal, cleaning and disinfection



Adhere to infection control protocols

# Medical systems for EID in US and Europe



**35** hospitals are designated as Ebola  
Treatment Centers



EID patients (VHF or MERS) will be gathered  
at **One** Hospital (Royal Free hospital) in London



EID patients (VHF or MERS) will be gathered at  
**2** hospitals (each 1 hospital in north / south area)

405 is too big number !!

# Treatment of ebola in developed countries

- In the outbreak of Ebola virus disease in West Africa from 2014 to 2015, the mortality rate was 39.5%
- Whereas the mortality rate was reduced to 18.5% by carrying in MedEvac and performing intensive care in developed countries.

# Our proposition

- 405 hospitals should be divided into 2 types of hospitals.
  - Treatment hospitals: Hospitals for EID diagnosis and treatment.
  - Assessment hospitals: Hospitals only for EID diagnosis.
  - Medical resources and staff should be collected in the treatment hospital.
- If not, MERS should be type I infectious diseases in law.

# Conclusion

- MERS is highly contagious EID with high mortality rate.
- In developed countries, it is required not only to isolate patients but also to save their lives.
- Medical resources and staff should be more concentrated and roles divided in each hospitals.